A new, multi-ethnic study found older adults with low vitamin K levels were more likely to die within 13 years compared to those whose vitamin K levels were adequate. The results suggest vitamin K, a nutrient found in leafy greens and vegetable oils, may have protective health benefits as one ages, according to the researchers.
Vitamin K, important for maintaining healthy blood vessels, is found in leafy greens, such as lettuce, kale and spinach, and in some vegetable oils, especially soybean and canola.
The meta-analysis, involving nearly 4,000 Americans aged 54-76, one-third of whom were non-white, was led by researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University (USDA HNRCA) and Tufts Medical Center and is published in The American Journal of Clinical Nutrition.
The research team categorized participants according to their vitamin K blood levels. They then compared risk of heart disease and risk of death across the categories over approximately 13 years of follow-up.
The results showed no significant associations between vitamin K levels and heart disease. However, the people with the lowest vitamin K levels had a 19 percent higher risk of death, compared to the those with vitamin K levels that reflected adequate vitamin K intake.
- Among 3891 participants (mean age 65 ± 11 y; 55% women; 35% nonwhite), there were 858 incident CVD events and 1209 deaths over a median of 13.0 years.
- The risk of CVD did not significantly differ according to circulating phylloquinone [fully adjusted HR (95% CI) relative to >1.0 nmol/L: ≤0.5 nmol/L, 1.12 (0.94, 1.33); >0.5–1.0 nmol/L, 1.02 (0.86, 1.20)].
- Participants with ≤0.5 nmol/L circulating phylloquinone had an adjusted 19% higher risk of all-cause mortality compared with those with >1.0 nmol/L [fully adjusted HR (95% CI): 1.19 (1.03, 1.38)].
- Mortality risk was similar in participants with >0.5–1.0 nmol/L compared with >1.0 nmol/L [fully adjusted HR (95% CI): 1.04 (0.92, 1.17)].
“The possibility that vitamin K is linked to heart disease and mortality is based on our knowledge about proteins in vascular tissue that require vitamin K to function. These proteins help prevent calcium from building up in artery walls, and without enough vitamin K, they are less functional,” said first author Kyla Shea.
Shea is a scientist on the HNRCA’s vitamin K team, long renowned for its work on the role of vitamin K in the prevention of chronic disease. Sarah Booth, a co-author on the study and director of the USDA HNRCA, developed the methodology for measuring vitamin K in blood. Her research team measured the vitamin K levels in the study participants and continues to generate data about vitamin K status in population and clinic-based studies.
“Similar to when a rubber band dries out and loses its elasticity, when veins and arteries are calcified, blood pumps less efficiently, causing a variety of complications. That is why measuring risk of death, in a study such as this, may better capture the spectrum of events associated with worsening vascular health,” said last author Daniel Weiner, M.D., nephrologist at Tufts Medical Center, whose research includes vascular disease in people with impaired kidney function.
While this study adds to existing evidence that vitamin K may have protective health benefits, it cannot establish a causal relationship between low vitamin K levels and risk of death because it is observational. Additional studies are also needed to clarify why circulating vitamin K was associated with risk for death but not heart disease.
The study is a meta-analysis, which combined data from participants in three ongoing studies: the Health, Aging, and Body Composition Study, the Multi-Ethnic Study of Atherosclerosis, and the Framingham Heart Study (Offspring Cohort). Vitamin K levels for participants in all three studies were measured after fasting, with the same test, and processed at the same laboratory (the vitamin K laboratory at the USDA HNRCA), minimizing the potential for laboratory-based variation. The test showed levels of circulating phylloquinone, the compound known as vitamin K1.
Participants on the blood thinner warfarin were excluded because vitamin K counteracts the anti-clotting effects of warfarin. All participants were free of heart disease at baseline and had vitamin K levels measured during a single medical exam that was part of each study’s regular protocol.
The statistical analysis adjusted for age, gender, race, ethnicity, BMI, triglycerides, cholesterol levels, smoking status, and use of medications for diabetes or high blood pressure.
There are some limitations to the study, including that circulating phylloquinone was measured from a single blood draw, rather than from repeated blood tests over time. Higher circulating phylloquinone may reflect an overall healthier diet and lifestyle. Lastly, there were fewer heart disease events compared to total deaths, which may have limited researchers’ ability to detect statistically significant risk of heart disease.
Conclusion/ Low circulating phylloquinone concentrations were associated with an increased risk of all-cause mortality, but not of CVD. Additional studies are needed to clarify the mechanism underlying this association and evaluate the impact of increased phylloquinone intake on cardiovascular and other health outcomes in individuals with low vitamin K status.